OrganiGram Holdings
Market Cap
CA$584.9m
Last Updated
2020/02/19 01:35 UTC
Data Sources
Company Financials +
Executive Summary
OrganiGram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with adequate balance sheet.
Similar Companies
Share Price & News
How has OrganiGram Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OGI's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
22.2%
OGI
6.6%
CA Pharmaceuticals
0.2%
CA Market
1 Year Return
-54.6%
OGI
-58.3%
CA Pharmaceuticals
4.9%
CA Market
Return vs Industry: OGI exceeded the Canadian Pharmaceuticals industry which returned -57.9% over the past year.
Return vs Market: OGI underperformed the Canadian Market which returned 5.8% over the past year.
Shareholder returns
| OGI | Industry | Market | |
|---|---|---|---|
| 7 Day | 22.2% | 6.6% | 0.2% |
| 30 Day | -15.0% | -14.5% | 0.4% |
| 90 Day | -6.5% | -15.3% | 3.7% |
| 1 Year | -54.6%-54.6% | -58.3%-58.3% | 8.2%4.9% |
| 3 Year | 32.6%32.6% | 10.7%10.0% | 15.9%5.5% |
| 5 Year | 588.5%588.5% | 303.6%303.6% | 33.8%14.3% |
Price Volatility Vs. Market
How volatile is OrganiGram Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
Can You Imagine How Elated OrganiGram Holdings's (TSE:OGI) Shareholders Feel About Its 512% Share Price Gain?1 month ago | Simply Wall St
Earnings Release: Here's Why Analysts Cut Their OrganiGram Holdings Inc. Price Target To CA$6.281 month ago | Simply Wall St
What Type Of Shareholder Owns OrganiGram Holdings Inc.'s (TSE:OGI)?Valuation
Is OrganiGram Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OGI (CA$3.55) is trading below our estimate of fair value (CA$22.2)
Significantly Below Fair Value: OGI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OGI is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: OGI is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OGI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OGI is overvalued based on its PB Ratio (1.7x) compared to the CA Pharmaceuticals industry average (1.4x).
Next Steps
Future Growth
How is OrganiGram Holdings forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
52.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OGI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: OGI is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OGI's is expected to become profitable in the next 3 years.
Revenue vs Market: OGI's revenue (26.6% per year) is forecast to grow faster than the Canadian market (5% per year).
High Growth Revenue: OGI's revenue (26.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OGI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has OrganiGram Holdings performed over the past 5 years?
29.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OGI is currently unprofitable.
Growing Profit Margin: OGI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OGI is unprofitable, but has reduced losses over the past 5 years at a rate of 29.3% per year.
Accelerating Growth: Unable to compare OGI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OGI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-11.3%).
Return on Equity
High ROE: OGI has a negative Return on Equity (-12.13%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is OrganiGram Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: OGI's short term assets (CA$191.8M) exceed its short term liabilities (CA$49.0M).
Long Term Liabilities: OGI's short term assets (CA$191.8M) exceed its long term liabilities (CA$91.7M).
Debt to Equity History and Analysis
Debt Level: OGI's debt to equity ratio (25.7%) is considered satisfactory.
Reducing Debt: OGI's debt to equity ratio has reduced from 36.3% to 25.7% over the past 5 years.
Balance Sheet
Inventory Level: OGI has a high level of physical assets or inventory.
Debt Coverage by Assets: OGI's debt is covered by short term assets (assets are 2.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OGI has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: OGI has been profitable on average in the past, therefore cash runway is not a concern.
Next Steps
Dividend
What is OrganiGram Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate OGI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OGI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OGI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OGI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OGI's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Greg Engel (54yo)
2.9yrs
Tenure
CA$1,074,643
Compensation
Mr. Gregory Engel, also known as Greg, has been Chief Executive Officer of OrganiGram Holdings Inc. since March 13, 2017. Mr. Engel has served in a number of senior-level and executive positions in related ...
CEO Compensation Analysis
Compensation vs Market: Greg's total compensation ($USD812.32K) is about average for companies of similar size in the Canadian market ($USD963.71K).
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | CA$1.07m | 0.046% CA$268.5k | |
| Chief Financial Officer | 2.2yrs | CA$852.71k | 0.028% CA$164.5k | |
| Senior Vice President of Marketing & Communications | 0.8yrs | CA$487.16k | 0.044% CA$256.1k | |
| Senior Vice President of Sales & Commercial Operations | 2.3yrs | CA$563.50k | no data | |
| Vice President of Operations | 0yrs | no data | 0.014% CA$79.8k | |
| Vice President of Investor Relations | 1.1yrs | no data | no data | |
| Senior VP of Strategic & Legal Affairs and Company Secretary | 0.8yrs | no data | no data | |
| Chief of Staff | 0yrs | no data | no data | |
| Vice President of International Business Development | 2.3yrs | CA$222.73k | no data | |
| Director of Finance | 2.2yrs | CA$143.13k | no data |
2.2yrs
Average Tenure
46yo
Average Age
Experienced Management: OGI's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.9yrs | CA$1.07m | 0.046% CA$268.5k | |
| Chairman & Lead Director | 1.9yrs | CA$502.60k | 0.098% CA$572.8k | |
| Independent Director | 2.2yrs | CA$469.00k | 0.0040% CA$23.5k | |
| Independent Director | 1.2yrs | CA$283.45k | 0.0036% CA$21.0k | |
| Independent Director | 5.1yrs | CA$472.75k | no data | |
| Independent Director | 1.2yrs | CA$280.71k | 0.0043% CA$25.0k |
2.0yrs
Average Tenure
54yo
Average Age
Experienced Board: OGI's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: OGI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.2%.
Top Shareholders
Company Information
OrganiGram Holdings Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: OrganiGram Holdings Inc.
- Ticker: OGI
- Exchange: TSX
- Founded: 2013
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$584.907m
- Shares outstanding: 163.38m
- Website: https://www.organigram.ca
Number of Employees
Location
- OrganiGram Holdings Inc.
- 35 English Drive
- Moncton
- New Brunswick
- E1E 3X3
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OGI | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Aug 2014 |
| OGI | NasdaqGS (Nasdaq Global Select) | Yes | Common Shares | US | USD | Aug 2014 |
| 0OG | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Aug 2014 |
| 0VB6 | LSE (London Stock Exchange) | Yes | Common Shares | GB | CAD | Aug 2014 |
Biography
OrganiGram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers cannabis flowers, cannabis oils, and pre-rolls for adult recreational consumers under the Edison Reserve, Edison Cannabis Co., ANKR Organics, and Trail Blazer brand names; and medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for the medical market. The company also engages in the wholesale shipping of medical cannabis plant cuttings and dried flowers. It sells its products through online, as well as telephone channels. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/19 01:35 |
| End of Day Share Price | 2020/02/18 00:00 |
| Earnings | 2019/11/30 |
| Annual Earnings | 2019/08/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.